Management of dyslipidaemia in patients with type 2 diabetes in Australian primary care

Medical Journal of Australia

Volumn 186, Issue 3, 2007, Pages 128-130

  Thomas, Merlin C ^a   Nestel, Paul J ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; AUSTRALIA; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES CONTROL; DIET RESTRICTION; DYSLIPIDEMIA; FEMALE; FREQUENCY ANALYSIS; GENERAL PRACTITIONER; HEALTH CARE DELIVERY; HEALTH SURVEY; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIMARY PREVENTION;

EID: 33847265380     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2007.tb00835.x     Document Type: Article

References (10)

1. Vijan S, Hayward RA. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med 2004; 140: 650-658.
2. Charles J, Ng A, Miller G. Management of type 2 diabetes in Australian general practice. Aust Fam Phys 2006; 35: 378-379.
3. Thomas MC, Weekes AJ, Broadley OJ, et al. The burden of chronic kidney disease in Australian patients with type 2 diabetes (the NEFRON study). Med J Aust 2006; 185: 140-144.
4. Stevens RJ, Kothari V, Adler AI, Stratton IM; United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond) 2001; 101: 671-679.
5. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459-467.
6. Putzer G, Roetzheim R, Ramirez AM, et al. Compliance with recommendations for lipid management among patients with type 2 diabetes in an academic family practice. J Am Board Fam Pract 2004; 17: 101-107.
7. Marcelino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med 1996; 100: 605-610.
8. Kulkarni SP, Alexander KP, Lytle B, et al. Long-term adherence with cardiovascular drug regimens. Am Heart J 2006; 151: 185-191.
9. Raffel OC, White HD. Drug insight: statin use in the elderly. Nat Clin Pract Cardiovasc Med 2006; 3: 318-328.
10. Blackburn DF, Dobson RT, Blackburn JL, Wilson TW. Cardiovascular morbidity associated with nonadherence to statin therapy. Pharmacotherapy 2005; 25: 1035-1043.